Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort
Objective: To examine longitudinal change in the clinical characteristics of non-manifesting LRRK2 mutation carriers (NMCs) compared to healthy controls (HC) in the Parkinson’s Progression Markers…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson’s Disease: Exploratory Efficacy Outcomes
Objective: To report secondary and exploratory analysis of efficacy of nilotinib in moderate/advanced Parkinson’s disease (PD) participants enrolled in NILO-PD study. Background: Previously completed studies…Resistance Training on Postural Control in Parkinson’s Disease: a Randomized Controlled Trial
Objective: To evaluate changes in postural control following RT using static posturography and clinical functional balance tests in Parkinson’s Disease patients Background: Muscle weakness affects…Dose Optimization of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: Clinical and Exposure Response Findings
Objective: Evaluate if dose optimization (DO) of apomorphine sublingual film (APL-130277; APL) can achieve improved FULL “ON” response in patients with Parkinson’s disease (PD) and…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…Deep Brain Stimulation impact on Social and Occupational Function in Parkinson’s Disease with Early Motor Complications
Objective: To investigate the effect of DBS compared with BMT on social, psychosocial and occupational functioning in PD patients ≤ 60 years of age with…Improving automaticity of walking in Parkinson’s disease: Levodopa or Donepezil?
Objective: Determine whether levodopa replacement or cholinergic augmentation improve automaticity of walking in people with Parkinson’s disease (PD). Background: Degradation of dopaminergic striatal mechanisms of…Helicobacter pylori eradication in Parkinson’s disease: A double-blind randomized placebo-controlled study
Objective: To evaluate the effects of Helicobacter pylori eradication on PD symptoms. Background: Globally, H. pylori infection remains a common problem. Cross-sectional studies in Parkinson's disease (PD)…Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Remote video-based research visits in a phase 3 clinical trial in Parkinson’s disease
Objective: To assess the feasibility, reliability, and value of remote visits in a phase 3 trial of individuals with Parkinson's disease (PD). Background: Remote video-based…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.